Search Results
Your search for ,led matches 5950 pages
Showing 5801 - 5850No Overall Survival Benefit With Addition of Sunitinib to Prednisone in Metastatic Castration-Resistant Prostate Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Michaelson et al assessed the addition of the antiangiogenesis agent sunitinib (Sutent) to prednisone in patients with progressive metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. No...
Adjuvant Bisphosphonates Improve Breast Cancer Survival, Reduce Bone Recurrence in Postmenopausal Women With Early Disease
Adjuvant use of bisphosphonates reduced the risk of bone recurrence by 34% and the risk of breast cancer death by 17% in postmenopausal women with early breast cancer in a large meta-analysis conducted by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). The potentially...
Nonsignificant Reduction in Breast Cancer Risk Seen With Low-Dose Tamoxifen in Postmenopausal Hormone Replacement Therapy Users
In postmenopausal women receiving hormone replacement therapy, low-dose tamoxifen did not significantly reduce the risk of breast cancer but did increase climacteric symptoms, according to the phase III study results presented by DeCensi et al in the Annals of Oncology. However, beneficial trends...
NeoALTTO Trial Links Pathologic Complete Response to Clinical Outcomes
Final results of the phase III NeoALTTO trial have confirmed the value of pathologic complete response to dual HER2 blockade in the neoadjuvant setting. The achievement of pathologic complete response was associated with significantly improved event-free survival and overall survival in some women...
No Difference Between Temsirolimus/Bevacizumab vs Interferon Alfa/Bevacizumab in First-Line Therapy for Metastatic Renal Cell Carcinoma
In the phase III INTORACT trial reported in the Journal of Clinical Oncology, Rini et al compared temsirolimus (Torisel)/bevacizumab (Avastin) vs interferon alfa/bevacizumab in first-line treatment of metastatic renal cell carcinoma. There were no significant differences between the two regimens in ...
Continuous Lenalidomide/Low-Dose Dexamethasone Improves Survival vs Standard Treatment in Older Patients With Newly Diagnosed Myeloma
First-line treatment of newly diagnosed multiple myeloma using continuous treatment with the doublet of lenalidomide (Revlimid) and low-dose dexamethasone was superior to standard triplet treatment with melphalan, prednisone, and thalidomide (Thalomid) for 72 weeks, according to initial results of...
Obinutuzumab/Chlorambucil Superior to Rituximab/Chlorambucil as First-Line Treatment for Older CLL Patients With Comorbidities
Obinutuzumab (Gazyva) plus chlorambucil (Leukeran) was superior to rituximab (Rituximab) plus chlorambucil as first-line therapy in older chronic lymphocytic leukemia (CLL) patients with comorbidities, with an acceptable safety profile, according to final results of the phase III CLL11 trial....
Vorinostat Plus Standard Immunoprophylaxis Cuts Risk of Graft-vs-Host Disease in Half
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of bone marrow transplant treatments, according to a study by Choi et al published in The Lancet Oncology. The study, the first to test this treatment in humans, combined the drug vorinostat...
Digital Breast Tomosynthesis Increases Cancer Detection and Reduces Recall Rates
Compared to traditional mammography, three-dimensional (3D) mammography—known as digital breast tomosynthesis—found 22% more breast cancers and led to fewer call-backs in a large screening study at the Hospital of the University of Pennsylvania, researchers reported today at the 99th...
Over-Regulation of Opioids Is Resulting in Untreated Cancer Pain for Millions of Patients Worldwide
The results from the European Society for Medical Oncology (ESMO)-led Global Opioid Policy Initiative (GOPI) project show that due to a lack of access to essential opioids, more than 4 billion people—over half the world’s population—live in countries where regulatory barriers,...
Tasquinimod May Improve Survival in Men With Metastatic Prostate Cancer
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds...
Gemtuzumab Ozogamicin Reduces Minimal Residual Disease in Children With High-Risk Acute Myeloid Leukemia
Combining gemtuzumab ozogamicin (Mylotarg) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s Research Hospital. The results appear in the...
Alternate VEGF Ligands Associated With Bevacizumab Resistance in Metastatic Colorectal Cancer
Results from a University of Colorado Cancer Center study indicated that bevacizumab (Avastin) resistance in patients with colorectal cancer may be due to increases in growth factors other than the targeted VEGF-A. The study, led by Christopher Lieu, MD, and published in the journal PLoS One,...
Dasatinib Plus Docetaxel Does Not Improve Overall Survival in Men With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Data suggest that Src kinase-mediated interactions between prostate cancer cells and osteoclasts might promote bone metastasis and that the Src kinase inhibitor dasatinib (Sprycel) might exhibit synergy with docetaxel in prostate cancer. In a phase III trial (READY) reported in The Lancet Oncology, ...
Young Breast Cancer Patients With Poorer Financial Status May Experience Delays in Seeking Care
Researchers seeking to determine why breast cancers are more deadly in young women found that although only a minority of young women experience long delays between the time they detect a breast abnormality and the time they receive a diagnosis, delays in seeking care are more common in women with...
Imaging Studies May Predict Tumor Response to Antiangiogenic Drugs
Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with antiangiogenic drugs and which will not. In a report published online in PNAS, researchers studied patients with newly diagnosed glioblastoma who were treated with the antiangiogenic agent...
Palliative Care Services and Outcomes Improve Using a Standardized Approach
Standardized criteria for initiating palliative care consultations can substantially improve the care of patients with advanced solid tumors, according to research from Mount Sinai School of Medicine, New York, led by Kerin Adelson, MD, Coordinator for Ambulatory Oncology Quality for the Tisch...
No Progression-Free Survival Difference With First-Line Axitinib vs Sorafenib in Metastatic Renal Cell Carcinoma
In a phase III trial reported in The Lancet Oncology, Thomas E. Hutson, DO, PharmD, of Baylor Sammons Cancer Center and colleagues compared the second-generation VEGFR inhibitor axitinib (Inlyta) with sorafenib (Nexavar) as first-line treatment of metastatic renal cell carcinoma. There was no...
Bone Marrow Transplant Linked to Negative Sexual Side Effects in Both Men and Women
New research ties preparative procedures and complications associated with blood or bone marrow transplant with diminished sexual health in both men and women who have undergone the procedure. Study data, published today in Blood, confirm chronic graft-vs-host disease as a potential source of...
Addition of Nab-Paclitaxel to Gemcitabine Improves Survival in Previously Untreated Metastatic Pancreatic Cancer
In a phase III trial reported in The New England Journal of Medicine, Daniel D. Von Hoff, MD, of Translational Genomics Research Institute in Phoenix, and colleagues assessed the addition of nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) to gemcitabine in patients with previously untreated...
Sequential Addition of Gemtuzumab Ozogamicin to Standard Chemotherapy of No Benefit in Older Patients With Newly Diagnosed AML
In a phase III trial (EORTC [European Organisation for Research and Treatment of Cancer]/GIMEMA [Gruppo Italiano Malattie Ematologiche dell’Adulto] consortium AML-17 trial) reported in the Journal of Clinical Oncology, Sergio Amadori, MD, of Tor Vergata University Hospital in Rome, and...
Potential New Drug Effective in Breast Cancer and Melanoma Resistant to Targeted Therapies
LEE011, an investigational small-molecule inhibitor of cyclin-dependent kinase (CDK) 4/6, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, according to findings presented at the AACR-NCI-EORTC...
Investigational EGFR Inhibitor May Hold Promise for Some Patients With Treatment-Resistant NSCLC
Approximately 50% of non–small cell lung cancer (NSCLC) patients who develop resistance to inhibitors of the epidermal growth factor receptor (EGFR) have acquired a second mutation, T790M, which no current EGFR inhibitors target. This may change if the AstraZeneca investigational compound...
Improved Progression-Free but Not Overall Survival With Addition of Maintenance Erlotinib to Bevacizumab After Chemotherapy Plus Bevacizumab in NSCLC
In the phase IIIB ATLAS trial reported in the Journal of Clinical Oncology, Bruce E. Johnson, MD, of Dana-Farber Cancer Institute, and colleagues assessed the addition of maintenance erlotinib (Tarceva) to bevacizumab (Avastin) following chemotherapy plus bevacizumab in first-line treatment of ...
STAG2 Mutation Found Linked to Low-Risk Bladder Cancer
An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer. The findings, published in Nature Genetics, identified STAG2 as one of the most commonly mutated genes in bladder cancer,...
Researchers Identify Four Genetic Variants Linked to Esophageal Cancer and Barrett’s Esophagus
An international consortium co-led by researchers at Fred Hutchinson Cancer Research Center and the QIMR Berghofer Medical Research Institute in Australia has identified four genetic variants associated with an increased risk of esophageal cancer and its precursor, Barrett’s esophagus. The...
LAT Inhibition May Be a New Therapeutic Option for Metastatic Castration-Resistant Prostate Cancer
L-type amino acid transporters (LAT) uptake neutral amino acids including L-leucine into cells, stimulating mTOR complex 1 (mTORC1) signaling and protein synthesis. LAT1 and LAT3 are overexpressed at different stages of prostate cancer and are involved in increasing nutrients and stimulating cell...
Everolimus Does Not Improve Overall Survival in Previously Treated Advanced Gastric Cancer
In a phase III trial (GRANITE-1 study) reported in Journal of Clinical Oncology by Atsushi Ohtsu, MD, PhD, of the National Cancer Center Hospital East in Kashiwa, Japan, and colleagues, everolimus (Afinitor) plus best supportive care did not prolong overall survival compared with placebo plus best...
Better Leukemia-Free and Overall Survival in AML in First Remission With Cyclophosphamide Plus Busulfan vs Total-Body Irradiation
Myeloablative conditioning with cyclophosphamide combined with intravenous busulfan (Busulfex) was associated with better leukemia-free and overall survival than conditioning with cyclosphosphamide and total-body irradiation in patients with acute myeloid leukemia (AML) who were in first complete...
Intervention Program Improves Sun Protection Practices Among Children of Melanoma Survivors
Children of melanoma survivors were more likely to wear hats and reapply sunscreen after receiving a multimedia informational program designed specifically for them. These new findings were included in research published in Cancer Epidemiology, Biomarkers & Prevention. A team of researchers...
Poorer Overall Survival With Sunitinib vs Sorafenib in Advanced Hepatocellular Cancer
In an open-label phase III superiority/noninferiority trial reported in Journal of Clinical Oncology by Ann-Lii Cheng, MD, of National Taiwan University Hospital in Taipei, sunitinib (Sutent) was associated with significantly poorer overall survival compared with sorafenib (Nexavar) in a population ...
Long-Term Follow-up Indicates Increased Telomere Length With Lifestyle Change in Men With Low-Risk Prostate Cancer
Short telomere length in peripheral blood mononuclear cells is associated with aging and such age-related diseases as cancer, stroke, vascular dementia, cardiovascular disease, obesity, osteoporosis, and diabetes. Telomere attrition is considered a potential mechanism in triggering the chromosomal...
Lactation May Be Linked to Triple-Negative Breast Cancer in Mexican Women
Scientific data suggest that a woman reduces her risk of breast cancer by breastfeeding, having multiple children, and giving birth at a younger age. However, a study led by the University of California, San Diego School of Medicine, indicates that women of Mexican descent may not fit that profile. ...
ECC 2013: Molecular Sequencing Identifies Drug Targets for Cancers of Unknown Primary Origin
Cancers of unknown primary origin pose a treatment dilemma for oncologists and a great deal of anxiety for patients and their families. A study reported at the European Cancer Congress 2013 in Amsterdam (Abstract LBA39) shows that molecular profiling can identify targetable mutations in up to 80%...
Telomere Length May Be a Prognostic Marker for Prostate Cancer
Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by scientists at Johns Hopkins. "Doctors are looking for new ways to accurately predict...
Abiraterone Acetate/Prednisone Combination Delays Decline in Quality of Life in Men With Metastatic Prostate Cancer
According to a study published in The Lancet Oncology, abiraterone acetate (Zytiga) taken in conjunction with prednisone significantly delays progression of pain and quality of life deterioration in men with metastatic castration-resistant prostate cancer. The study was led by Ethan Basch, MD,...
Scientists Find Possible Antidote for Tamoxifen-Induced Mental Fog
Researchers from University of Rochester Medical Center have shown scientifically what many women report anecdotally: that tamoxifen is toxic to cells of the brain and central nervous system (CNS), producing mental fogginess similar to “chemo brain.” In the study, published in the...
Statement by ASCO President Clifford A. Hudis, MD, FACP, in Support of the Rally for Medical Research Hill Day
“With the unprecedented scientific opportunities now promising significant progress against cancer and other life-threatening diseases, it is a tragedy that we are even considering cuts to our nation's investment in biomedical research. Yet, such cuts are already happening because of the...
MicroRNA Molecule Found to Be a Potent Tumor Suppressor in Lung Cancer
New research shows that microRNA-486 (miR-486) is a potent tumor-suppressor molecule in lung cancer, and that it helps regulate the proliferation and migration of lung cancer cells, as well as the induction of apoptosis in those cells. Published in the Proceedings of the National Academy of...
PDK1 Gene Identified as New Target for Melanoma Treatment
According to new research at Sanford-Burnham Medical Research Institute a gene encoding the enzyme phosphoinositide-dependent kinase-1 (PDK1) plays an essential role in the development and progression of melanoma. The finding, published online in Oncogene, may offer insight toward a new approach to ...
Addition of Bevacizumab to Capecitabine Improves Progression-Free Survival in Elderly Patients with Previously Untreated Metastatic Colorectal Cancer
Elderly patients are often underrepresented in clinical trials of metastatic colorectal cancer. In a phase III study (AVEX trial) reported in The Lancet Oncology, David Cunningham, MD, of Royal Marsden Hospital in London and colleagues assessed the addition of bevacizumab (Avastin) to capecitabine...
FDA Grants Volasertib Breakthrough Therapy Designation in Acute Myeloid Leukemia
Boehringer Ingelheim Pharmaceuticals, Inc, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase (Plk), which being evaluated for the treatment of patients aged 65 or older with...
AACR Issues 2013 Cancer Progress Report
The American Association for Cancer Research (AACR) released its Cancer Progress Report 2013 today. And while there is much to celebrate in the significant progress made in cancer research—which has led to more effective therapies for the more than 200 types of cancer and increased...
Gene Expression–Based Biomarker Predicts Long-Term Risk of Breast Cancer Recurrence
A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor–positive breast cancer found that only the breast cancer index (BCI)—a biomarker based on the expression levels of seven tumor-specific genes—accurately identified patients...
Test Could Identify Which Prostate Cancers Require Treatment
The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center (CUMC). Use of this three-gene...
Dana-Farber Mourns the Passing of Jane Carrie Weeks, MD, MSc, National Leader in Outcomes Research
Jane Carrie Weeks, MD, MSc, a prominent researcher at Dana-Farber Cancer Institute, internationally known for building the discipline of outcomes research in oncology and admired by colleagues as an outstanding mentor, died September 10 after a long illness. She was "one of the true intellectual...
Pomalidomide Plus Low-Dose Dexamethasone Improves Survival vs High-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
Pomalidomide (Pomalyst) alone has shown limited efficacy in relapsed multiple myeloma, but synergistic effects have been noted when it is combined with dexamethasone. In a phase III trial (MM-003) reported in The Lancet Oncology, Jesus San Miguel, MD, of Universidad de Salamanca, and colleagues...
Dr. Larry Norton, Honored at 2013 Breast Cancer Symposium, Calls for Return to the ‘Exploration of Concepts’
Larry Norton, MD, of Memorial Sloan-Kettering Cancer Center, is the recipient of the 2013 Gianni Bonadonna Breast Cancer Award, which he received at the 2013 Breast Cancer Symposium. The Symposium is sponsored by ASCO, the American Society of Breast Surgeons, the American Society of Radiation...
Majority of Breast Cancer Deaths Occur in Younger, Unscreened Women, Study Finds
A new analysis has found that most deaths from breast cancer occur in younger women who do not receive regular mammograms. Published early online in Cancer, the study indicates that regular screening before age 50 should be encouraged. The use of mammograms to prevent breast cancer deaths has been ...
Cabozantinib Improves Disease-Free Survival in Progressive Medullary Thyroid Cancer
Cabozantinib (Cometriq) is an inhibitor of hepatocyte growth factor receptor (MET), VEGFR2, and rearranged during transfection (RET) tyrosine kinases. In a phase III trial reported in Journal of Clinical Oncology, Rosella Elisei, MD, of the University of Pisa, and colleagues found that cabozantinib ...
